| Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled … J Rosenstock, M Hanefeld, P Shamanna, KW Min, G Boka, P Miossec, ... Journal of Diabetes and its Complications 28 (3), 386-392, 2014 | 138 | 2014 |
| Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5 PD Home, P Shamanna, M Stewart, F Yang, M Miller, C Perry, MC Carr Diabetes, Obesity and Metabolism 17 (2), 179-187, 2015 | 120 | 2015 |
| Reducing HbA1c in type 2 diabetes using digital twin technology-enabled precision nutrition: a retrospective analysis P Shamanna, B Saboo, S Damodharan, J Mohammed, M Mohamed, ... Diabetes Therapy 11, 2703-2714, 2020 | 72 | 2020 |
| Blood pressure control with a single-pill combination of indapamide sustained-release and amlodipine in patients with hypertension: the EFFICIENT study U Jadhav, J Hiremath, DJ Namjoshi, VK Gujral, KK Tripathi, M Siraj, ... PLos one 9 (4), e92955, 2014 | 54 | 2014 |
| Efficacy and safety of remogliflozin etabonate, a new sodium glucose co-transporter-2 inhibitor, in patients with type 2 diabetes mellitus: a 24-week, randomized, double-blind … M Dharmalingam, SR Aravind, H Thacker, S Paramesh, B Mohan, ... Drugs 80, 587-600, 2020 | 43 | 2020 |
| Retrospective study of glycemic variability, BMI, and blood pressure in diabetes patients in the Digital Twin Precision Treatment Program P Shamanna, M Dharmalingam, R Sahay, J Mohammed, M Mohamed, ... Scientific Reports 11 (1), 14892, 2021 | 26 | 2021 |
| Efficacy and safety of lixisenatide once daily versus placebo in patients with T2DM insufficiently controlled on sulfonylurea±metformin (GetGoal-S) R Ratner, M Hanefeld, P Shamanna, K Min, G Boka, P Miossec, ... Diabetologia 54 (Suppl 1), A785, 2011 | 19 | 2011 |
| Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on sulfonylurea+/-metformin (GetGoal-S) RE Ratner, M Hanefeld, P Shamanna, K Min, G Boka, P Miossec, ... Diabetologia 54, S317-S317, 2011 | 18 | 2011 |
| Type 2 diabetes reversal with digital twin technology-enabled precision nutrition and staging of reversal: a retrospective cohort study P Shamanna, S Joshi, L Shah, M Dharmalingam, B Saboo, J Mohammed, ... Clinical Diabetes and Endocrinology 7, 1-8, 2021 | 17 | 2021 |
| Digital Twin Enabled Personalized Nutrition Improves Metabolic Dysfunction-Associated Fatty Liver Disease in Type 2 Diabetes: Results of a 1-Year Randomized Controlled Study S Joshi, P Shamanna, M Dharmalingam, A Vadavi, A Keshavamurthy, ... Endocrine Practice, 2023 | 10 | 2023 |
| Post-meal pharmacodynamic profile of lixisenatide once daily vs placebo in T2DM insufficiently controlled on SU±metformin (GetGoal-S) RE Ratner, M Hanefeld, P Shamanna, KW Min, G Boka, P Miossec, ... IDF World Diabetes Congress, 2011 | 8 | 2011 |
| Harmony 5 year 3 results: albiglutide vs. placebo and vs. pioglitazone in triple therapy (background metformin and glimepiride) in people with type 2 diabetes P Home, M Stewart, J Mallory, D Miller, C Perry, P Shamanna, MC Carr Diabetes 63, A247-A247, 2014 | 4 | 2014 |
| 26-OR: metabolic benefits beyond glycemic control with artificial intelligence, internet of things, and whole-body digital twin: initial six months results of a randomized … SR JOSHI, L SHAH, M MOHAMED, J MOHAMMED, T POON, ... Diabetes 71 (Supplement_1), 2022 | 3 | 2022 |
| Harmony 5-year 3 results: albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in people with type 2 diabetes P Shamanna, P Home, MW Stewart, JM Mallory, DM Miller, CR Perry, ... 50th EASD Annual Meeting, 2014 | 2 | 2014 |
| Safety and efficacy of liraglutide in type 2 diabetes: post marketing surveillance data from India SK Wangnoo, A Mithal, S Kumar, KD Modi, P Shamanna, R Shetty Diabetologia 55, S299-S299, 2012 | 2 | 2012 |
| Digital Twin in Managing Hypertension Among People With Type 2 Diabetes: 1-Year Randomized Controlled Trial P Shamanna, S Joshi, M Dharmalingam, A Vadavi, A Keshavamurthy, ... JACC: Advances, 101172, 2024 | 1 | 2024 |
| Observational, Multicenter, Retrospective, Study on the Usage Patterns of the Fixed Dose Combination of Glimepiride, Metformin, and Voglibose in Type 2 Diabetes Management P Shamanna, PK Jha, A Makwana, H Shukla, C Bavishi Cureus 16 (1), 2024 | 1 | 2024 |
| Abstract# 1413498: whole body digital twin technology for remission of T2DM and normalization of glycemic and fatty liver parameters: 1 Year intent to treat analysis of the … S Joshi, M Dharmalingam, A Keshavamurthy, A Vadavi, B Saboo, ... Endocrine Practice 29 (5), S28, 2023 | 1 | 2023 |
| PSUN230 Concordance between HbA1c, eA1C and fasting plasma glucose criteria to define type 2 diabetes remission: Insights from the Six months of Digital Twin Intervention Trial P Shamanna, M Dharmalingam, A Vadavi, B Saboo, S Damodaran, ... Journal of the Endocrine Society 6 (Supplement_1), A385-A385, 2022 | 1 | 2022 |
| OZ101, an oligofructose prebiotic, may prolong sulphonylurea efficcy in patients with type 2 diabetes: a pilot study: OZ101 and sulphonylurea-mediated glycaemic control NN Gorgani, KHS Kim, WL Free, M Afkham, JD Henson, P Shamanna, ... Journal of Current Medical Research and Opinion 5 (06), 1235-1251, 2022 | 1 | 2022 |
Dr. S. Mohamed Thajudeen在 twinhealth.com 的电子邮件经过验证
